COMBIVIR - 49349-683-12 - (lamivudine and zidovudine)

Alphabetical Index


Drug Information of COMBIVIR

Product NDC: 49349-683
Proprietary Name: COMBIVIR
Non Proprietary Name: lamivudine and zidovudine
Active Ingredient(s): 150; 300    mg/1; mg/1 & nbsp;   lamivudine and zidovudine
Administration Route(s): ORAL
Dosage Form(s): TABLET, FILM COATED
Coding System: National Drug Codes(NDC)

Labeler Information of COMBIVIR

Product NDC: 49349-683
Labeler Name: REMEDYREPACK INC.
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: NDA020857
Marketing Category: NDA
Start Marketing Date: 20130423

Package Information of COMBIVIR

Package NDC: 49349-683-12
Package Description: 8 TABLET, FILM COATED in 1 BLISTER PACK (49349-683-12)

NDC Information of COMBIVIR

NDC Code 49349-683-12
Proprietary Name COMBIVIR
Package Description 8 TABLET, FILM COATED in 1 BLISTER PACK (49349-683-12)
Product NDC 49349-683
Product Type Name HUMAN PRESCRIPTION DRUG
Non Proprietary Name lamivudine and zidovudine
Dosage Form Name TABLET, FILM COATED
Route Name ORAL
Start Marketing Date 20130423
Marketing Category Name NDA
Labeler Name REMEDYREPACK INC.
Substance Name LAMIVUDINE; ZIDOVUDINE
Strength Number 150; 300
Strength Unit mg/1; mg/1
Pharmaceutical Classes Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA]

Complete Information of COMBIVIR


General Information